STOCK TITAN
  1. Home
  2. Sec-filings
  3. MLYS
  4. [Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Mineralys Therapeutics director reports option exercises and share sales. A company director filed a Form 4 showing multiple stock option exercises on November 11–13, 2025 at exercise prices of $10.20 and $12.69 per share, followed by same-day open market sales of the resulting common shares at prices around $42.43–$47.28.

After these transactions, the reporting person held no shares of common stock directly, but continued to hold 34,000 stock options with exercise prices of $10.20 and $12.69, expiring in 2034 and 2035 and vesting in monthly installments.

Positive

  • None.

Negative

  • None.
Insider Gold Alexander M
Role Director
Sold 34,675 shs ($1.58M)
Type Security Shares Price Value
Exercise Stock Option 2,742 $0.00 --
Exercise Stock Option 10,000 $0.00 --
Exercise Common Stock 2,742 $10.20 $28K
Exercise Common Stock 10,000 $12.69 $127K
Sale Common Stock 12,742 $46.50 $593K
Exercise Stock Option 6,933 $0.00 --
Exercise Common Stock 6,933 $10.20 $71K
Sale Common Stock 5,000 $46.50 $233K
Sale Common Stock 1,933 $47.2766 $91K
Exercise Stock Option 15,000 $0.00 --
Exercise Common Stock 15,000 $10.20 $153K
Sale Common Stock 10,000 $42.4298 $424K
Sale Common Stock 5,000 $47.0816 $235K
Holdings After Transaction: Stock Option — 8,225 shares (Direct); Common Stock — 2,742 shares (Direct)
Footnotes (1)
  1. The stock option vests in 12 monthly installments following the date of grant. The stock option vests in 36 monthly installments beginning on July 13, 2024.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gold Alexander M
(Last) (First) (Middle)
150 N. RADNOR CHESTER ROAD, SUITE F200
(Street)
RADNOR PA 19087
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/11/2025 M 15,000 A $10.2 15,000 D
Common Stock 11/11/2025 S 10,000 D $42.4298 5,000 D
Common Stock 11/11/2025 S 5,000 D $47.0816 0 D
Common Stock 11/12/2025 M 6,933 A $10.2 6,933 D
Common Stock 11/12/2025 S 5,000 D $46.5 1,933 D
Common Stock 11/12/2025 S 1,933 D $47.2766 0 D
Common Stock 11/13/2025 M 2,742 A $10.2 2,742 D
Common Stock 11/13/2025 M 10,000 A $12.69 12,742 D
Common Stock 11/13/2025 S 12,742 D $46.5 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $10.2 11/11/2025 M 15,000 (1) 02/13/2035 Common Stock 15,000 $0 17,900 D
Stock Option $10.2 11/12/2025 M 6,933 (1) 02/13/2035 Common Stock 6,933 $0 10,967 D
Stock Option $10.2 11/13/2025 M 2,742 (1) 02/13/2035 Common Stock 2,742 $0 8,225 D
Stock Option $12.69 11/13/2025 M 10,000 (2) 06/13/2034 Common Stock 10,000 $0 34,000 D
Explanation of Responses:
1. The stock option vests in 12 monthly installments following the date of grant.
2. The stock option vests in 36 monthly installments beginning on July 13, 2024.
Remarks:
/s/ Adam Levy, Attorney-in-fact 11/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR